FA
DNA icon

FDx Advisors’s Ginkgo Bioworks DNA Stock Holding History

FDx Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,256
Closed -$220K – 426
2023
Q4 		$220K Buy
3,256
+282
+9% +$17.3K 0.02% 627
2023
Q3 		$215K Buy
2,974
+344
+13% +$27.5K 0.02% 583
2023
Q2 		$196K Buy
2,630
+1,235
+89% +$73.1K 0.01% 719
2023
Q1 		$94K Hold
1,395
– – ﹤0.01% 734
2022
Q4 		$94K Buy
1,395
+141
+11% +$13K ﹤0.01% 734
2022
Q3 		$156K Buy
1,254
+56
+5% +$6.67K 0.01% 701
2022
Q2 		$114K Buy
1,198
+267
+29% +$32.6K ﹤0.01% 789
2022
Q1 		$150K Buy
+931
New +$181K 0.01% 806

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FDx Advisors's DNA Position: Q1 2024 in Review

FDx Advisors sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 3,256 shares — an estimated $220K sold.

FDx Advisors first reported a position in DNA in Q1 2022 and held it in 8 quarters. The position peaked at $220K in Q4 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

  • FDx Advisors reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
  • FDx Advisors sold 3,256 Ginkgo Bioworks shares in Q1 2024, an estimated $220K.
  • FDx Advisors first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 8 quarters.
  • FDx Advisors's Ginkgo Bioworks position peaked at $220K in Q4 2023.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on FDx Advisors's 13F filing for Q1 2024, filed 3 May 2024.